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Abstract
Background: Opioid use is a severe problem in Iran. Despite methadone maintenance treatment (MMT) programs
being one of the most important treatment strategies for reducing individual and public harms associated with
opioid use, a large proportion of Iranian patients refuse to participate in such treatment programs.
Methods: The present study aims to explore the beliefs and attitudes toward MMT programs of opioid-dependent
patients who were participating or had participated in methadone therapy. In-depth interviews were conducted
with 23 opioid users between 27 and 58 years of age from Kurdistan provinces.
Results: Overall, six themes were discovered to be key barriers relating to methadone treatment, including financial
barriers related to methadone treatment, lack of awareness about methadone treatment, negative attitudes regarding
using methadone, worries about methadone’s side effects, social stigma ascribed to methadone therapy, and systemic
barriers to methadone treatment.
Conclusion: Our study revealed that the cost of treatment is a major obstacle to attending and continuing at MMT
programs and that addicts and their families are not always accurately informed about the duration of MMT programs
and the side effects of methadone treatment.
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Background
The United Nations Office on Drugs and Crime
(UNODC) reported that in 2013, the universal preva-
lence of opioid use among adults was around 0.7%,
which ranked opioids as the second most common form
of illicit drug used worldwide. Opioid use has a long his-
tory in Iran, as a result of which there is some level of
social tolerance toward it in some regions [1, 2].
Although opium is the dominant type of opioid used in
Iran, over time, the pattern of opioid use in Iran has
changed into other types of opioids, such as shireh,
heroin, and kerack-heroin [1]. Opioid use harms individ-
uals physically and psychiatrically, imposes economic
and social burdens on society and raises huge public
health concerns in Iran [3] as well as internationally
[4–12]. Beyond the health burdens of opioid use dis-
order on individuals and communities, dependence on
drugs hinders economic productivity and diminishes hu-
man capital [8, 13]. In addition, opioid markets increase
illegal careers and negatively affect the resources avail-
able in legal economies [8, 12]. Illegal opioid markets are
also linked to rises in crime and social insecurity [5].
Methadone maintenance therapy (MMT) is the most
frequently used opioid therapy. It is readily available for
patients seeking opioid treatment in many countries
[14–16], and it was implemented in 60 out of 70 coun-
tries providing opioid treatment services (OTS) in 2009
[11]. Stable, prolonged MMT yields prominent benefits
to both patients and communities [15, 17]. Scientific evi-
dence has demonstrated that MMT has the capacity to
reduce the need to use opioids, particularly opioid
injection [6, 9, 16, 18]; decrease the adverse health
effects of drug use, such as fatal and nonfatal drug
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overdoses [12, 19, 20]; and keep patients in treatment
and decrease the risk of relapse to drug use [12, 18]. Fur-
thermore, MMT seems to improve HIV treatment out-
comes [6, 7, 9], reduce HIV and hepatitis transmission
[6, 13, 19], control dysfunctional behaviors [12], and
suppress criminal activities, notably drug-related crimes
such as drug dealing [6, 13, 21]. Studies have also shown
that stabilizing patients in MMT programs provides
them with a better chance to find and hold a suitable
job [16], work more productively, build strong family
and social relations [16, 22], and enhance their quality of
life [16, 22, 23]. All these returns ultimately have a posi-
tive influence on public health and security as well as
human capital and social productivity [5, 8, 16]. MMT is
also a more cost-effective treatment intervention than
other opioid maintenance treatments. For instance, a re-
search study conducted in California during 2000 and
2001 found that substance abuse treatment has a
benefit-to-cost ratio greater than 7:1 [24]. There is evi-
dence that in low- and middle-income countries where
there is a lack of treatment programs, the expansion of
MMT programs might lead to savings in social and
health expenditures [12, 19, 25].
In recent years, more than 80% of the recognized
drug-treatment seekers in Iran were primarily dependent
on opioids [3, 26]. Although buprenorphine mainten-
ance therapy (BMT), a well-known type of OST, is now
available in Iran, MMT programs are the most fre-
quently used therapy [1, 11]. Originally, MMT programs
were launched in Iran as a harm-reduction initiative.
After a successful pilot test in 2002 in the Iranian Na-
tional Center for Addiction Studies (INCAS), the MMT
program has implemented in public and private clinical
centers. By the end of 2009 there were approximately
16,000 clinical sites established by the Ministry of Health
nationwide that provided MMT program services for
159,000 opioid-dependent patients according to treat-
ment protocols [1]. The cost of MMT services is differ-
ent in governmental and private centers. On average,
patients have to pay $20–$30 monthly in governmental
centers. This fee is considerably higher in private
centers.
Even though MMT programs are one of the most im-
portant treatment strategies for reducing individual and
public harms associated with opioid use, and despite the
central role of MMT in harm-reduction approaches to
opioid use in Iran and many other countries, previous
studies have pointed out that a large proportion of eli-
gible patients refuse to participate in this type of treat-
ment program [4, 5, 13, 27, 28]. What is more, many
participating patients seem to drop out of such programs
[5, 28]. According to evidence, various obstacles, notably
the perception of barriers related to MMT as well as
misconceptions that opioid replacement treatment can
cure the addiction problem in the short run, negatively
affect patients’ entrance and adherence to MMT pro-
grams, respectively, and hinder satisfying treatment out-
comes [4–6, 13, 16, 19, 28]. Better knowledge about the
obstacles perceived by opioid users could provide policy
makers and practitioners with a guide to attracting a
greater proportion of opioid patients to treatment pro-
grams and ensuring patients’ compliance with treatment
[5]. To the best of our knowledge, no study has focused
on the obstacles to entering MMT programs from the
perspective of opioid-dependent patients in Iran. To fill
this gap in the existing literature, the present qualitative
study aims to explore the beliefs and attitudes toward
MMT programs of opioid-dependent patients who were
participating or had participated in an MMT.
Methods
Participants
Between February and July 2016, we conducted 23
in-depth qualitative interviews with opioid users in Kur-
distan province, Iran. About half (n = 12) of the partici-
pants were users who were currently in MMT. Seven of
the other participants had formerly been using metha-
done but dropped out of MMT, and four of the other
opioid users had never begun MMT. An Institutional
Review Board (IRB) approved this research, and ethical
approval was obtained from the Kurdistan University of
Medical Sciences IR.94/97. Written informed consent
was also obtained from all participants.
The inclusion criteria for this study were: (1) being
20 years old or older and (2) being an opioid user. In
order to gain different viewpoints, a purposive sampling
method with maximum variation was used. Four MMT
clinics were randomly chosen from a total of 10 MMT
clinics in the Kurdistan province. To gain maximum
variation, we opted to recruit opioid users from different
age groups with different socioeconomic, educational,
and occupational levels, varying religiosity, and different
marital statuses.
Data collection
Open-ended questions were used in the 23 in-depth in-
terviews, which were performed using a semi-structured
interview guide. Each interview started with an opening
question in which the researcher asked the respondents
about their experiences with MMT. Depending on the
topics that were brought up by the respondents, the
researcher chose other questions that touched on their
experiences with MMT. Examples of questions were “Do
you consider MMT to be efficacious?”, “What problems
have you experienced with MMT?”, “If you discontinued
the treatment, what were the reasons and problems that
you experienced?”, “What positive or negative experi-
ences did you gain from treatment with methadone?”,
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“Did you experience side effects from methadone, and if
so, which side effects?” and “What was the perspective
of family and friends on the regular use of methadone as
a treatment?” Depending on the participants’ responses,
the moderators rephrased some questions or asked add-
itional questions if they wanted to delve deeper into spe-
cific issues that were brought up by the respondents.
Examples included “What do you mean?” and “Can you
explain this more?” We recorded our analytical concept
by memo writing. Each interview lasted for approxi-
mately 1.5 to 2 h and was conducted in an isolated room
by an expert interviewer. Data were collected until satur-
ation was obtained.
Data analysis
Data were analyzed with MAXQDA software using Gran-
eheim and Lundman’s method [29]. A qualitative content
analysis with a conventional approach was applied to the
information gained from the semi-structured interviews in
order to detect the semantic units. Immediately after the
interviews, the recorded interviews were typewritten.
Transcriptions were analyzed and coded so that the next
interviews were directed by information obtained from
the previous interviews. The following steps were applied
for qualitative data analysis. First, the transcripts were read
and reread by the researchers, and then important quotes
were highlighted. In the following step, meaning units
were produced from the statements. In order to elicit pri-
mary codes, a comparative analysis was applied. Then,
themes and subthemes were constructed based on the
codes with similar meanings.
Results
Description of study sample
The twenty-three opioid users who participated in the
present study were between 27 and 58 years old with a
mean age of 43.27 years. Due to a lack of cooperation
from treatment centers in which female drug users are
treated, this study was conducted among male drug
users only. Most of the men (n = 15) were married, and
less than a quarter (n = 3; 13%) had never been married.
The participants had various levels of education: five
(21.6%) had completed higher education, four (17.4%)
had completed secondary or high school education, and
14 (61%) had completed fewer than six years of educa-
tion (primary school). Fourteen participants (61%) were
employed. All but two participants used tobacco, seven
used crack-heroin on a regular basis, 12 reported that
they used heroin, and four used other illegal drugs.
Overall, six main themes were discovered as key barriers
relating to MMT, including financial barriers related to
MMT, lack of awareness about MMT, negative attitudes
toward using methadone, worries about methadone side
effects, social stigma ascribed to MMT, and systemic bar-
riers to MMT.
Theme #1: Financial barriers related to methadone
treatment
Although some participants had accepted entering treat-
ment, they did not enter treatment because of financial
problems, and as a result they continued using drugs
and were unable to get MMT. Unemployment and the
high cost of MMT were the biggest barriers to entering
treatment for some participants. Patients had to expend
more cash, which came mostly from their families, and
it was common for them to request more money from
their families, which may have placed a financial burden
on their family.
“I’m speaking about myself… As a known addicted per-
son I couldn’t have a good job, thus any income... I
couldn’t pay the methadone fee. My father wants to
financially support the treatment cost, but he makes
below 7000,000 rial per month. Methadone costs
1,300,000 rial per month, not counting transportation.
How much is needed for their day-to-day costs? He is get-
ting older … what do I do after he dies?” (P7; 58 years
old, divorced, high school education, currently using
MMT, a heroin user).
The participants without work were also dependent on
family members to support their MMT. Some partici-
pants who did not get financial support from their fam-
ily were not able to be treated with methadone. Besides
the treatment fee, the day-to-day transportation costs
were also a financial burden. As three of the patients re-
ported, “My wife provides for our living expenses with
carpet weaving and crafts, which pay little. The price of
the cure is very high, 40,500 rials every day. I have a
good family and they are really supportive, but my
family’s financial ability is too poor ... and because I’m
unemployed, it is really hard for me.” (P11; 42 years old,
married, university education, currently using MMT, a
heroin user).
Another man said, “I had a lot of problems during
treatment: unemployment and lack of money because of
this, the cost of renting a house. Sometimes I even did not
pay for treatment, because the cost of MMT was not so
much lower and I could pay for drugs instead. The gov-
ernment does not support us for the cost of treatment,
but I have a good family. They are really supportive, but
my family’s financial ability is poor. And because I’m un-
employed ... it is really hard for me.” (P7; 55 years old,
divorced, primary school education, currently using
MMT, a heroin user).
Additionally, participants frequently said that a lack of
insurance is a major barrier to entering clinics or MMT
programs. Having no insurance or being unable to pay
for insurance may not be an issue in most developed
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countries that have a community health system that pro-
vides coverage for treating people with addictions, but it
is a major problem for patients in Iran.
One patient said, “I am a daytime construction worker.
I only earn money on the days that I find work. Some-
times, I really do not have the money to pay for my
methadone. I wish that the insurance would cover my
addictin treatment.” (P14, 46 years old, married, second-
ary school education, a heroin user).
Theme #2: Lack of awareness about methadone
treatment
Patients generally do not know the nature of MMT and
have unrealistic expectations of treatment. The majority
of patients think they will be able to put their drug use
aside forever and that they will experience just a few
months of methadone addiction problems. However,
using methadone for only a few months is incompatible
with the goals of MMT harm-reduction programs, in
which the goal is to increase patients’ health and to
avoid physical side effects. Most of the participants felt
that they had received inadequate information about
methadone. One patient said,
“Unfortunately I was addicted to heroin for eight
months. Now I’m here at the MMT center. I have never
received information on MMT at any time. Before I was
an addict, I haven’t been in conditions where I’ve been
required to connect with addicted people; consequently, I
have never been in a condition where I’ve had to hear
about methadone.” (P5; 43 years old, divorced, college
education, an opium user).
The majority of the patients also reported a lack of
knowledge about the duration and doses of methadone
treatment.
“When I entered the MMT, I thought that I could grad-
ually reduce the dose of methadone and gradually cut off
methadone, so that I would quit drugs forever. But after
the four years that I have been treated with methadone,
I’m still taking methadone. And recently, I found that it
might be forever that I will use methadone.” (P19;
52 years old, married, high school education, a heroin
user).
Another participant stated,
“The doctors never told me that I should use metha-
done for a long period. They always give us delusive
hope... If I had known from the beginning that MMT was
prolonged, perhaps I would have never used it.” (P22;
45 years old, married, primary school education, a
crack-heroin user).
Theme #3 negative attitudes regarding using methadone
Participants had different and mixed beliefs about
methadone. Some of these beliefs were negative. A mis-
trust of MMT and fear of becoming dependent on
methadone were observed between participants. Some
participants mentioned that they had no desire to be
treated with methadone due to the rate of relapse in
MMT compared to treatments for other drugs. Of
course, this comparison may serve as a justification in
the case of patients who do not want to continue treat-
ment, or it could mean that some successful participants
in MMT may not be an illustrative or actual sample of
patients who have not entered MMT as compared to pa-
tients who have entered MMT and also remained in
treatment. This viewpoint becomes clearer in the follow-
ing statement:
“I have no desire to be treated by methadone. I believe
that methadone is more addictive than opioids. One of
my friends was on MMT, but he had to use heroin at the
same time due to a lack of effect. Therefore, I believe it
isn’t effective.” (P6; 29 years old, single, college education,
a crack-heroin user).
Some participants had worries and fears about
MMT and believed it was stupid to exchange one
drug with another. During MMT, the dose of metha-
done is reduced at the discretion of the clinic. Some
patients have difficulties accepting this because they
still feel the need to use drugs. As such, patients ex-
perience problems withdrawing from methadone and
believe methadone withdrawal is more difficult than
heroin withdrawal.
“Withdrawing from methadone is more difficult than
withdrawing from heroin. It causes severe bone pain and
emotional pain. It is like an insect biting your body. I
don’t know how to explain this experience. Further, one
side effect is that you need to sleep more.” (P12; 40 years
old, primary school education, married, crack-heroin
user).
As another participant stated,
“I think that MMT is more addictive than other opi-
oids, and it is more difficult to quit from it. I am not go-
ing to use methadone once more due to its addictive
nature. I prefer to use other opioids.” (P8; 34 years old,
primary school education, single, heroin user).
Theme #4 worries about methadone side effects
While the side effects of methadone that were reported
by patients who get treatment did not appear to be very
strong, they nevertheless caused worries, and worries
about the side effects were one of the main reasons for
giving up MMT. The level of worry about methadone
side effects varied among the participants enrolled in
MMT. The most frequently mentioned methadone side
effects were sleep disturbances, dizziness, decreased sex-
ual desire, itching, vomiting, bloating, liver disorders,
diarrhea, and constipation. Some patients reported that
these effects disrupted their family and work life. One
interviewee complained,
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“It almost decreased my sexual desire! It was more se-
vere than consuming hashish. Most of the people who
have been treated by methadone report the same symp-
toms as I have. My wife thought that I had a girlfriend.
She didn’t understand me. She thought that I was betray-
ing her at that time.” P10; 41 years old, married, high
school education, a crack-heroin user).
In addition, most of the patients had not been in-
formed about the side effects of methadone. Some of
them were unable to get information about the side ef-
fects from the methadone clinic, due to a lack of profes-
sional doctors. However, some of them were also unable
to find suitable treatment for methadone side effects in
other medical clinics. Some clinics said to the patients
that the key solution to these problems was reducing the
methadone dose. However, reducing the dosage of
methadone might result in mental or physical problems.
With regard to these side effects, some patients ac-
knowledged that they received a response to their ques-
tions from the methadone clinic staff. One participant
stated,
“At the beginning of the treatment, I did not receive
any information about methadone side effects. During
seven months using methadone, I faced many problems,
including erection problems. I went to the doctor. He said
that this was because of the methadone. Unfortunately, I
did not get any information beforehand from the clinical
staff about the side effects of methadone. I was really
afraid about the side effects of it!” (P14, 46 years old,
married, secondary school education, a heroin user).
Others mentioned perspectives on the side effects of
methadone that might serve as a warning about future
methadone treatment. The following sentences show
some of the patients’ viewpoints:
“Methadone is worse than crack-heroin. It is actually a
risky drug. It makes my bones breakable. And as a habit
it’s worse than heroin. I would rather take hashish than
methadone. I got a friend that was treated with metha-
done: he used 100 milligrams methadone, and he died
after eight months.” (P1; 55 years old, married, high
school education, a heroin user).
Theme #5: Social stigma ascribed to methadone therapy
Most patients generally reported social stigma toward
methadone users as one of the reasons why opioid users
did not want to be treated by methadone. The fear of
stigma was worsened by society’s negative attitude to-
ward people with addictions. The participants explained
their experiences of being rejected once their opioid use
became recognized by other persons in society. Add-
itionally, these participants explained that they have low
expectations of creating a new, nonstigmatized identity,
even after a long period of opioid withdrawal. Patients
described that being known as an opioid addict would
probably result in a rejection by society. A current opi-
oid user reported the following reason why he rejects
using methadone:
“When my family sees that I use methadone syrup, I
am ashamed. Even when they remind me that I must use
methadone and I must not forget the syrup, I am embar-
rassed. Although my family knows that I am treated with
methadone, I feel bad.” (P10; 41 years old, married, high
school education, a crack user).
“Frankly speaking, when I get methadone from the
clinics, I am worried that if one of my family members
sees me in the MMT center, they will reject me... I’m
addicted and I understand that my treatment gives a
very bad reputation to my family.” (P12; 40 years old,
primary school education, married, crack user).
Other participants gave the following statements:
“As a methadone user, the community rejects you.
They’re still looking at you as an opioid user. Nobody
(except my addicted friends) wants a relationship with
me. I’ve become like a wasteful person. My identity is
very shameful.” (P8; 34 years old, primary school educa-
tion, single, heroin user).
“There is one more thing about methadone that I want
to say: some people look at us in a different manner. Un-
fortunately, people only look negatively at methadone...
People who are not using methadone believe that
addicted persons who are getting methadone are still
addicted.” (P12; 40 years old, primary education, mar-
ried, crack user).
Some participants mentioned that they did not want
to be treated by methadone in an MMT or public clinic
because it would cause them to be known in public as
an addicted person. Three participants explained their
viewpoint in the following way:
“When you go to a methadone clinic, your name is reg-
istered. I want my identity to be unknown, so I won’t be
able to go to a methadone clinic.” (P9; 41 years old, sin-
gle, a heroin user).
“It’s true that for months I have not used heroin, but I
do not feel clean at all. Maybe I’m no longer addicted to
heroin, but now I’m a methadone addict. And I know
that if people know that I’m addicted to methadone, they
do not think so well about me.” (P13; 41 years old, mar-
ried, high school education, a crack user).
“Once at the airport, at an inspection, one of the agents
took notice of my methadone pills and reminded my col-
leagues to carefully check my suitcase. It was as if she
was facing a suspect who gave her a bad feeling.” (P9;
41 years old, single, a heroin user).
Theme #6 systemic barriers in methadone treatment
Almost all of the patients said there were systemic bar-
riers to treatment with methadone, including lack of
support from specialist services, inappropriate behavior
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with patients, the necessity of regular visits to get
methadone, the time-consuming and long duration of
the treatment, and strict laws.
Participants stated that they had a tendency to reuse
drugs when they faced some behavior from therapists.
“Every morning, I must go to the methadone center for
my treatment and take my daily methadone. I have to
do that during my working hours. My boss is not happy
with this. I wish they could give some methadone for a
week to some patients.” (P11; 32 years old, single, college
education, a heroin user).
“I do think that therapists have a main role to play,
since one might assume that they have experience about
addicted persons, but many of them have not behaved
well toward us. They could take care of us in a better
way, especially in the beginning of treatment with metha-
done. But they are not taking enough time to provide us
with information to treat us. In my opinion, the majority
of therapists and physicians have looked at us in a hu-
miliating way... they look from a top-down perspective.”
(P13; 41 years old, married, high school education, a
crack user).
Having supportive services, like psychological counsel-
ing from therapists, seems to be an essential need for sev-
eral patients. However, it looks like these services are very
inadequate in the MMT clinics. The therapists have a high
workload and because they are too busy, they do not offer
enough information. Most participants reported that they
left MMTclinics without getting essential counseling from
a therapist. Some patients complained about the lack of
private areas for individual consultation with therapists.
As one participant said,
“You know, I did not get any education or counseling.
I hoped that the physicians would talk with me for a
moment, but they didn’t. In my opinion, having more
counseling would be extremely valued. I was hoping that
the therapists could explain how to avoid drugs... Now I
feel like I just get the dose of methadone every day with-
out any patient’s rights.” (P8; 34 years old, primary
school education, single, heroin user).
“My family asked me whether I went today to a center
to get methadone. ... I said yes... I went to a gas station
though… [laughing] I think the clinics are like petrol sta-
tions. We take methadone so that we can stand and con-
tinue our life. No adviser.... No teacher.... No warning.”
(P9; 41 years old, single, a heroin user).
Patients also complained about the length of the treat-
ment, the necessity of regular visits to get methadone,
and the time-consuming aspects of the treatment
process, which are all interlinked:
“The main problem is that methadone treatment takes
a while. We also have to be present a long time before-
hand to get methadone at the MMT. If the duration of
treatment would be shorter, I think that we would cope
better with the difficulties of the treatment process.” (P16;
33 years old, college education, single, crack user).
Logistical barriers and rigid rules presented another
kind of systemic barrier that was reported by partici-
pants. Some patients reported that a short time after the
beginning of treatment with methadone, they returned
to using their previous drug of choice because the open
hours of the MMT clinics did not match their working
hours. Furthermore, employed patients had many prob-
lems when going out of the city for business. Due to
these problems, many of the participants explained that
they had no intention to enter a long-term MMT pro-
gram. Two participants explained their viewpoint in the
following way:
“I am a normal worker. My working hours are from 7
am to 5 pm. I need this job to continue my life. On the
other hand, the clinicians work from 8 am to 5 pm. Be-
cause I must go to work at 7 am, I cannot come to the
clinic. I have to choose either to go to work or to go to a
clinic for treatment. I think it is my biggest problem.”
(P7; 58 years old, divorced, high school education, cur-
rently using MMT, a heroin user).
Another reason for patients’ dissatisfaction regarding
treatment with methadone was problems related to the
quality of methadone syrup.
“The first time that I received methadone syrup, I had
lost my craving and consumption. I was happy to con-
sume it, and I did not have any symptoms from taking it.
But after a while, it was as though the methadone qual-
ity was changed... waterier… As if it did not correspond
with the previous dose. When I told this to the techni-
cian, he said that the pharmaceutical company had been
changed. I had really severe constipation. My mouth was
dry, and this was so unbearable that I had to stop taking
methadone anymore.” (P9; 41 years old, single, a heroin
user).
“I have no problem with methadone tablets, but I don’t
like syrup. Generally, I have problems with eating, but
methadone tablets are easier to transport. It is easy to
measure the doses. For example, it is obvious how much
5 mg is... but for me, 5 ml syrup is difficult to measure. I
was afraid to drink too much or too little. But most Iran-
ian MMT centers offer patients syrup and not tablets.”
(P22; 45 years old, married, primary school education, a
crack user).
Discussion
To the best of our knowledge, this is the first study that
qualitatively presents the obstacles to attendance and ad-
herence to MMT programs as perceived by Iranian
opioid-dependent patients. Based on the personal stories
of the drug-dependent patients in MMT programs, we
identified six themes contributing to barriers to reten-
tion in MMT.
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Financial barriers related to methadone treatment
The majority of the interviewees reported the cost of
treatment as being a major obstacle to attendance
and continuing at MMT programs, especially for un-
employed and low-income patients. These findings
are in line with other studies [13, 19, 28] that reported
financial problems as a key factor that dissatisfies pa-
tients with treatments for drug use. Despite the large
number of Iranian drug-dependent patients seeking
treatment, insurance schemes do not cover all drug
treatments in Iran. It seems that reducing or eliminat-
ing drug-treatment costs would encourage more
drug-dependent patients to attend drug treatment and
to remain longer in the programs, which could im-
prove treatment outcomes [30, 31]. Since MMT as a
harm-reduction strategy benefits both patients and society
enormously [32], it would be highly effective to allocate
more financial resources to Iranian drug-treatment pro-
grams like MMT. Insurance coverage should be improved,
and it might be beneficial to provide financial support to
patients, such as a public transportation card for free or at
a discount rate.
Lack of awareness about methadone treatment
It is clearly shown that there are misconceptions regard-
ing MMT [5]. A large number of interviewees had some
unrealistic expectations of the drug treatment. Not
accepting opioid dependence as a chronic and relapsing
disorder, they expected methadone therapy to be a cura-
tive treatment that would last only for a short time and
treat their drug disorder quickly and completely. Lack of
awareness about MMT has been reported several times
[33, 34]. Also, negative attitudes toward MMT have been
reported in some studies [13, 35]. MMT as a prolonged
replacement treatment rather than a therapeutic treat-
ment is a barrier to attending such a program and com-
plying with its agenda [36]. As described by Xu, people
with drug dependence prefer short-term treatments [14].
A previous study demonstrated that health education in-
terventions may reduce patients’ misconceptions about
MMT, but can also raise the probability of dropout from
treatment [5]. However, Csete and colleagues [37] sug-
gested that decision-making about treatment agendas
should be carried out only by treatment practitioners,
and it seems that receiving thorough, clear information
regarding the nature of treatment is within the patient’s
rights. In this study, some of the interviewees reported
that practitioners or physicians demonstrated inappro-
priate, disruptive, and unfriendly behaviors, which
discouraged them from continuing treatment. Since ef-
fective patient-clinician relationships improve outcomes
and adherence to therapy [38], one strategy would be to
provide communication skills training programs for
Iranian practitioners.
Negative attitudes regarding methadone use
Our findings revealed that some of the interviewees were
skeptical about the effectiveness of MMT. In fact, few of
the interviewees believed that MMT could be a helpful
strategy for drug treatment. As suggested by Babrora
and colleagues, drug-dependent patients have less trust
in treatment systems [19]. One possible explanation
could be the high relapse rate among MMT participants.
A study conducted between 2007 and 2011 in Iran
found high rates of relapse among opioid-dependent pa-
tients participating in MMT, with 64% of patients relaps-
ing within six months after treatment admission [39]. As
suggested by previous studies, the effectiveness of MMT
has been increased by comprehensive services such as
psychological consultation, motivational enhancement
therapy, behavioral intervention, and structured relapse
prevention [16, 40, 41].
Ward has stressed the important role of staff in mak-
ing MMT programs efficacious [42]. Thus, a key factor
regarding the effectiveness of Iranian MMT programs
could be using well-trained staff who have good com-
munication skills and detailed knowledge about pa-
tients’ concerns about MMT therapy. An effective and
efficient way of offering training in physician-patient
communication is in the form of seminars or work-
shops where strategies are covered for improved com-
munication in a relatively short period of time. Also, we
found that the viewpoints of the patients’ family mem-
bers and relatives toward MMT could play a leading
role in patients’ motivation to comply with an MMT
program. In fact, social support not only improves
therapeutic responses but also has an effect on reten-
tion in treatment. Higher social support is related to
higher retention and completion of treatment [43, 44]. Also,
social support plays a role in decreasing stigmatization.
Having no or too little support from family or from MMT
workers may increase the risk of the recurrence of addiction
following a period of remission [45]. The process of treat-
ment is very stressful, and it is hard to stay clean without
support.
Several interviewees reported that their family mem-
bers were concerned about the long duration of MMT.
One explanation might be that long-term treatment
could make family members rather tired of supporting
dependent patients financially and emotionally. It seems
that many of the patients’ families are not familiar with
the fact that methadone treatment is a prolonged re-
placement therapy and not a short-term curative ther-
apy. Given that academics have suggested that family
support is related to retention for MMT [46], it could be
strongly suggested that all family members be educated
about MMT programs. Family members’ training is pos-
sible by holding group meetings and family counseling
sessions whenever patients are referred to methadone
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treatment. Educational interventions for family members
could change their attitudes toward MMT programs and
increase their knowledge about them, which could in
turn result in more support from family members to fol-
low MMT therapy.
Worries about methadone side effects
Most of the interviewees indicated that the side effects of
methadone were obstacles that hindered attending an
MMT program. Several interviewees had experienced
methadone therapy to have harmful effects on their liver
performances, teeth, and sexual performance. Also, some
complained of constipation during the treatment period.
This finding is consistent with a recent study of Stancliffin
that pointed out the negative effects of methadone on
teeth and bones [47, 48]. A recent study conducted in the
US found that drug-dependent patients believed that
methadone therapy might have adverse health effects [4].
Also, some interviewees undergoing MMT programs were
worried about methadone hangover symptoms and a dan-
ger of becoming methadone dependent. This result has
been confirmed in other studies [4, 18, 33, 47, 49, 50].
Not only do these concerns encourage a preference for
other treatment styles [14], but they also increase drop-
out rates among MMT participants. Some interviewees
participating in Iranian MMT programs expressed their
preference for not complying with the treatment agenda.
In fact, some of them used to reduce the methadone
doses gradually because they misunderstood the adverse
effects of high doses of methadone. In contrast, some
dependent patients participating in MMT programs in-
creased their methadone dose without a medical pre-
scription in order to eliminate the withdrawal symptoms
of retention. Therefore, we suggest providing patients
with effective modern (e.g., acupuncture) and traditional
medical treatments (e.g., painkillers in the short period
after starting treatment) to reduce the side effects of
MMT.
Social stigma ascribed to methadone therapy
The results of our study further indicated that the stigma
on MMT remains a great barrier to attendance at MMT
programs. Some of the interviewees in this study dropped
out of treatment because of suffering from severe embar-
rassment when going to MMT centers. These findings are
in line with those of other studies [16]. Some studies have
revealed that methadone-related stigma experienced by
drug users could influence their treatment decision-making
[51, 52]. Thus, policy makers should be responsible for pro-
viding a noncritical social environment for drug treatment
systems in order to remove or reduce stigma among the
public community toward Iranian individuals seeking these
treatment services. This could be done through mass media
or social media interventions.
Systemic barriers in methadone treatment
Iran has made remarkable progress in the establishment
of MMT clinical centers in recent years. It is estimated
that at least 1600 MMT clinics deliver treatment services
for more than 159,000 opioid-dependent patients in Iran
[1]. As a result, Iran is one of the most successful coun-
tries in implementing MMT. There are several systemic
barriers in the country that hinder attendance of MMT
programs.
Appearing to receive a daily dose in the first months of
treatment is a main perceived barrier to attending MMT
given the prolonged length of treatment. As mentioned by
some interviewees, daily referral to MMT clinics causes
patients serious difficulties in different areas related to
their jobs and families. Furthermore, daily referral is a
waste of patients’ time and makes them worry about being
seen. Our findings suggest that treatment services should
consider options such as take-home doses, which may im-
prove treatment compliance by eliminating the need for
daily attendance. Also, as shown by Gao and colleagues,
take-home dose services increase retention time and
improve treatment outcomes [53]. Furthermore, some
of the patients’ complaints against treatment systems
are related to the quality of methadone syrup provided
by different pharmaceutical companies. In addition,
some drug-dependent patients preferred to use metha-
done tablets rather than syrup due to the ease of carry-
ing and using them, whereas methadone is distributed
in the form of syrup in all MMT clinics in Iran.
Limitation
One limitation of the present study is that the small
sample size limits our ability to generalize the results to
other drug users. As such, the findings of the study
should be interpreted with caution.
Conclusions
This study aimed to explore barriers to and misconcep-
tions about MMT in Iranians with drug dependence.
Our findings suggest that Iranian people with addictions
and their families should be better informed about the
duration of MMT programs and the side effects of
MMT. In addition, addicts might be helped by reducing
the costs of MMT.
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